YMU1

YMU1 is an inhibitor of thymidylate kinase (TMPK, IC50 = 610 nM). It is selective for thymidylate kinase over thymidine kinase 1. YMU1 (2 and 10 µM) reduces deoxythymidine triphosphate (dTTP) levels by 30-40% in p58-/- HCT116 cells without affecting dATP, dGTP, or dCTP levels. It also sensitizes a variety of cancer cell lines to doxorubicin (Cay-15007), including p53+/+ and p53-/- HCT116, HT-29, SaoS2, MDA-MB-231, and MDA-MB-468 cells. YMU1 reduces tumor growth in a p53-/- HCT116 mouse xenograft model when administered at a dose of 5 mg/kg three times per week for four weeks.Formal Name: 4-[2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl]-1-piperazinecarboxylic acid, ethyl ester. CAS Number: 902589-96-2. Molecular Formula: C17H22N4O4S. Formula Weight: 378.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: Chloroform: 30 mg/ml, DMF: 0.30 mg/mL. lambdamax: 226, 254, 319 nm. SMILES: O=C(OCC)N1CCN(C(CN(SC2=C3C(C)=CC(C)=N2)C3=O)=O)CC1. InChi Code: InChI=1S/C17H22N4O4S/c1-4-25-17(24)20-7-5-19(6-8-20)13(22)10-21-16(23)14-11(2)9-12(3)18-15(14)26-21/h9H,4-8,10H2,1-3H3. InChi Key: XXUFNNVFZFVKGP-UHFFFAOYSA-N.